COVID-19 Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D01KSL
|
|||
Drug Name |
REGN3048 + REGN3051 mabs
|
|||
Drug Type |
Combination drug
|
|||
Indication | Middle East Respiratory Syndrome (MERS) | Discontinued in Phase 1 | [1] | |
Therapeutic Class |
Antiviral Agents
|
References | Top | |||
---|---|---|---|---|
1 | ClinicalTrials.gov (NCT03301090) A Safety, Tolerability, Pharmacokinetics and Immunogenicity Trial of Co-administered MERS-CoV Antibodies REGN3048 and REGN3051. U.S. National Institutes of Health. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.